CFB
TGTX icon

Cullen/Frost Bankers’s TG Therapeutics TGTX Stock Holding History

Cullen/Frost Bankers’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-132
Closed -$4.75K – 1441
2025
Q2 		$4.75K Buy
132
+81
+159% +$3.02K ﹤0.01% 1103
2025
Q1 		$2.01K Buy
+51
New +$1.72K ﹤0.01% 1163

Other funds holding TGTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Cullen/Frost Bankers's TGTX Position: Q3 2025 in Review

Cullen/Frost Bankers sold out of TG Therapeutics (TGTX) in Q3 2025, closing a stake of 132 shares — an estimated $4.75K sold.

Cullen/Frost Bankers first reported a position in TGTX in Q1 2025 and held it in 2 quarters. The position peaked at $4.75K in Q2 2025. 354 funds tracked by Wall St. Rank hold TGTX as of Q3 2025.

  • Cullen/Frost Bankers reported no remaining TG Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Cullen/Frost Bankers sold 132 TG Therapeutics shares in Q3 2025, an estimated $4.75K.
  • Cullen/Frost Bankers first reported a position in TG Therapeutics in Q1 2025 and held it in 2 quarters.
  • Cullen/Frost Bankers's TG Therapeutics position peaked at $4.75K in Q2 2025.
  • 354 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2025.

Based on Cullen/Frost Bankers's 13F filing for Q3 2025, filed 31 Oct 2025.